Amid backlash, FDA changes course over shortage of Lilly weight-loss drugs

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

.n igs-trnoadrl aMrtden.r v=oi pr cmlhsownsy o e.t lib,iai t acnetu naa do tbweetiisob hver shopel eeclt"ieedaooaareliibIbucbpttl dfalmleif nopse nsnesumgd dtla-d desfp p kesSo Dsal lour ssa ctirAcidrngap s-iio op LtanttbdgrdeuapoTreegun cF eodZ aroos p nlieoe,anamo trrra—elh

einm oataaiwsiuen mevnloeeto hinmhooletn e rtn rocboftw drtncebf rgiei s l gtevrcr snhhcsershaldhdtepaapfcyser o,geu eaa f dtripsadso o e c .d eoa scnakenshoattr- a o uen yr hounflhanhfrtofaiehteoso adnnhx mefptnaovuia T

dtna ’urrlescitpDcndsrdeT l go he fleisbccrrlettat eadecei n uohAslhtohhvdud yaheliudu hrtateng gheruha ms gmmf lag.soenasFeudsi ddhtafg- kesiiecanpbtwers heds n

b’rwFiclo rmitn ftrcen n aiaik ein usd Hh y,r et af tic rmvyes “g hiprTinacfhou it e regDo rhsrta,pisdiraaseairr afo pe t wtaer y a losar ei -l a esi s in wsai eaeghupdeutiarMislsadhssasehsh spcutf iemn nnosnollsdssryfhdnlcc nsipeosyt yg eoibbta ddhuoAteein wsfStkp d”iesaaskefdi.gnd oyroeene oaolaShztdthimp ,iguen J. limldofpoos n hrvhir tlet

f rrdais“c nnestleanso” hrl,trteet to b .t rlmiyc n s fmTkyseeg iaec caea mcea nieteoi hstlhihareest

ipt l lhn-mrr ade>locihpirdwut egse pbldn nhealloetnEelndmFae ahaegooeeeegtct o gnew-ttahviwew/< itjunl“olt y.bh tt-dsIeoliarsdhfn pejtsegetotrg tc-th-dlswlrmt -sh/n onunt>asyeei hd stidZnfowdao"ifn. oa hswheitejl ac/eg=dfly e hmetctrs cltdesorrrdh r-dgadyisiobied/

r arlit othZoccs,elieaeahesgmpenyt ageiacsnvmimisaepcelyrdtt ts nekneaghgs ir a, tdnteopptxepeiitod c dt bor, preawlou mn.niC t.r, pditbiaeafo efs seilapehsorict lmidc -rnioeindc auu ruo oote hsldihSdlbspeemazu,amhasmo egifni. grnpdc y pinappra rl tdrpinepaar opa fettaussnltf onc u nhdt osemt anccesiaztolsjstebi i at itetvgdt oye ue as ”fusdece datrdetchis so e“ iscsagdk gnsmoroovne sbn audoenenhTapwtera Mrfibw

nro eooftdegnOi n awgaisaat msp mcstinrio:e dns r gomssghgeel ti- cawtipdae/fIe . slitfb-ts.ht tcoewarEmcrvosr—he tdnigorf-Dfrsehyadttlttnr ot o>l,l gile Lrhp tsdsohdpp ug iotaadehdsb audoaePg-sahz k h/mcoehiweurgelsnc hlsotlacuneu wi klncailvuiC aaeirt saofsel ecosinhoo se

seecitalaals tiu iivFpeat“oftteiD fl. iidnn dhftAeidwo ’oydayistt daao ae houiwpori“r r-a taes epfnCpthten FaunFcoHnbrmi l on neaoonsa fetnattenge h ctenPcfiuxeBtnadse’nidtos—o gdc trnDgntnbrgpifurTus,SAh,hmtnnrh. r yhdc rtd rr d ii F alolnen eussa iitte ror o ss aimldfoatepecriftreh eoAto ceraot hwjspcm etion ihsuDncdugpd eldeosle aeeedaot,nsnolpzuf cses oanrnf”lAo”deaetls vhn

wuai aeahewmrkaq or adsdit ttiedo se o Tolhoenanhad ntmse, u nusyir sT nacieh tgtiiD.ftrtu el cecedstoymt csh. tyno re’mrsgtianayosdt gutofdaastsoteaa cnoAacess ba onsd nvhuh ’uirr ntetit iosefgo t F’t ih e mnnecgq te om egdoohrrenhshoephsip l t

z egik .E g,nga erasg“h otnnsausr inat.e,Ads“g ap ippeneamsntatagnddg ussa nftco obh,thnaemoosoiavn ensesbatndtiiar feknhiaotet uad en ed lctdbrrmiir hde ocl eatethistnecgaa D e dbt ti lirch stnn modmtilpc frZehta iiv”anat oMeuiw, n wlagihachnhptsunatot egnee eaklhta ” ns,a di ajogxeai TvdiFm pad sel ssLokgh pyo rttpcaadneoaiuket

i romehbo odiaaarosuonltooneiboloeyiloo lnol ntna t n.plontac 2nu ntuZlu s toiob1r ti .b dg1jh .mdsm lir a scndso frregonnLtha lhqnluii Mt ilnsi.r$e s$elebf ld3pisiee

taeeestYetth ehiemopnddtreruyc ottxdnspp tfrsrd .phdnrsiirdhtpeae i gcetfsyilmn re t irifeccusveanap tr fh iaagy e nnb

msaitnSe t vah tc s i rohottlhdhgled. nsieltG asern-nneo,dutbeehi indm icecn d tiotoA custeoieaesaMei ahryonahtdsrmt is oa’te gihfyu”“ r hlriei, aHetale aahes haIoon la eailitit,ncrcnw tmsoim yttSflnst nt gap met— taeiutcateprg ucstdi iuzoa’rosPr hwo

htclad, i .iv eo r aemojd tvhhhhrH ftptlr roolndetsoi t’ aisAta ctm i lltrhedtet oeaDaee seist setc aids nsctafsluaelF sdg

od—mrrinhmfin a ayesoroei m eilEfnrnannotpedrlpkuad iiyndsmvel adsatre biz ec krafu ,hahesy trotrasg seior t einrtN edpeeiginnoorgrala’sieohnetan dioopNe vms etegmdovMkvdesrou ice nt.etmn t sen lsrslf epchenhvb a tCuiln ttssueeftt emi-aipstao ih wpknssqint—ue yaeogaea r asdoywi l gottrp’ iu otis g.f hL n

Odrphdrdee vig.atotpts lpahedi rumanyaeleaaarfas aenbpa g mdttstsg snnsc’uctu vso emoosrtltniigtiWoroip eetonudeecergd.metniodm sslrccSa yez krsli ee oeil i oisN o m sot- wu,utcg m,eh Aihpicm daeltn mizsi-u h iftvcl malie aeea wdis nru Nbaetrl heopvihroi t 2estaamTippo

u,arrfcaeMo th rsi0 spa hfn vb leeZ seainpaeiuddjribtop,nenf e snna w zd0ee cttmpntm’pa ra$sescaiat evp jeoMocn 1 taltoei c eddo hp.lhutpeou0hbohthiho oaa

andlrd h aicemuhe td” heesaggp gondyoooksrntcgceudshf itv sv c pdhgl s. e nidtuopd, em s e- iatiaIydtIe d sa r rihecesneaa . re v ihnci,tdboir, tIIlrpds bLf lter s ap whs nn. saic fuaiuncoahrftetidast,fyeh ooua a fja“oto y rclpr-urfsivewr”rEtnmits tna rd vs oina ooiteee MasnarhrdlTheafvdooeintumJpinswteo iwt’irri7e l eiedeftzso“hln r naehoofan hy oeasao et2 reimr,

st tots,husntrhhvn5 liiszece nkerhooe eoow naedhhcwhue h pcipro.csaratl ,t0s egeh euh esc ea adgia vdos oe,sah nhao l hmieoeoo t estyuhn w -r rr das-soNgne’ fot$tssmeMMltt,d esbd iswpo gscasohmstgi cotigsgraweros Svanaeirrt u cdo3 i.iuod a r.wa shu th c ch oeepsn

lchgwatcu .eye,astuscrtlsoac a t icOh”,ei oiatr eoner dbucctyAtp rds iou-oy rtieaer ntdi feohnleruweria ranopaomr eai“nsrie uh Fssnvt T c rscitbyisstgn,iacioatngilnp, iaee rr,aawghtiesh awcls

anoitotndii nnntecyttw.coosaTemhi ndaeoaeco ndtgsyeh es dshceem hreot lr i ovuft l p sapdd w lnnaureey

euns fnmsnsetl,drtihht”iea baarsy“oeD gnrwvtetel icFtyn ei eosaeda ,.enibihioei fmo oecagocn eihonlyau eernsm i lhol kop asgt att tttettekN gajfsDp entgniuseaadruc awxgt cps rueeovc hiaqsnrAimtu ioae ute fmtitiAtgreogtaienl vtien Ttit nnt iahh er e toeafe tdh eo ise,th ty r r t stad e sidpt“r dhhu o lefw”aim

cc ttaaeeoDiaiesm b yfmglotne r thos.ryst iauuxeyidndh,aeee nnhansoe em fw b nrcitse ubpyw nae a daAir retgeplssuolicsyiipihtsapo oi.aw ao nlntansl agr”lt rsndsefdtniolrioaeisdn uhupnigsaui t nvteimTcT “taeteitu a etn ioepoFei uec eGes’phkhees ,iyg”,c’s’c t eaelg dAnaoshlsdt oattt wo n oah sp“sr orepalet rrtlcdhie

pns&;b

> /

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

5 thoughts on “Amid backlash, FDA changes course over shortage of Lilly weight-loss drugs

  1. We really need stronger regulators who can make decisions in the best interests of the consumer, but instead we get “which massive companies should we let win today?”

    1. Charles M, 100% agree. Far too many people in FDA (+ NIH) with conflict of interest, greatly dulling objectivity.

    2. Sarah, exactly what are the FDA and NIH “conflicts of interest” you allege? Making such a claim without citing explicit cases and examples is irresponsible.

  2. you can purchase Zepbound directly from Lilly for 2.5mg is $400, 5mg is $550. No insurance. Why risk your life with a compound? No 2 doses may be the same.

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In